Health Dictionary Find a Doctor

Wilson's disease

For patient information click here

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Cafer Zorkun, M.D., Ph.D. [2], Ahmed Elsaiey, MBBCH [3]

Synonyms and keywords: Hepatolenticular degeneration

Overview

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Elsaiey, MBBCH [2]

Overview

Wilson’s disease is a rare autosomal recessive inherited disease that occurs in both children and adults due to copper accumulation in different organs, mainly in the liver and the brain. Wilson’s disease is caused by genetic mutations in the ATP7B gene which is responsible for the transportation of the dietary copper to the liver. Copper is normaly absorbed in the stomach and transported to the liver in order to function properly as a cofactor for some enzymes as the cytochrome c oxidase enzyme. Copper is also incorporated in the formation of ceruloplasmin in the Trans Golgi network. Transportation of the copper to the Trans Golgi network occurs via ATOX1 protein and others are bound to metallothionein. Pathogenesis of Wilson’s disease include any impairment that may occur during copper transportation and incorporation into different essential metabolic mechanisms. The mechanisms responsible for the pathogenesis of Wilson’s disease include high serum copper level, accumulation of the copper in the liver, and deposition of the copper in different organs resulting in ultimate injury and organ damage. The prevalence of Wilson’s disease is estimated to be 3 cases per 100,000 individuals worldwide. Wilson’s disease affects individuals between 5 to 35 years old. Common risk factors of Wilson’s disease include newborns of disease-carrier parents. Less common risk factors include excess non-vegetarian diet. If left untreated, Wilson’s disease will lead to death as the copper accumulation in the liver and brain results in cirrhosis and severe dystonia, respectively. Common complications of Wilson’s disease include hepatocellular carcinoma, renal failure, and persistent neurological manifestations. Prognosis of Wilson’s disease is usually good in case of early detection and proper treatment. Patients with Wilson’s disease may remain asymptomatic until the copper deposits in the liver and brain mainly. Common hepatic symptoms include abdominal distension, abdominal pain, fatigue, bleeding tendency, and esophageal varices. Common neuropsychiatric symptoms include tremors, ataxia, dysarthria, and impulsiveness. Physical examination of patients with Wilson’s disease is usually remarkable for jaundice and easy bruising in the skin. Physical examination also is remarkable for Kayser-Fleischer ring in the eyes as a result of the copper accumulation in the cornea. Laboratory findings suggestive for Wilson’s disease include low ceruloplasmin level, high serum copper concentration and high urinary excretion of the copper. MRI scanning can be used in detecting brain abnormalities especially in the basal ganglia. Medical therapy is the mainstay of therapy for treatment patients with Wilson’s disease. The treatment option include penicillamine, trientine, and Zinc. Liver transplantation is reserved for the patients that present with acute liver failure and unresponsive to the medical treatment.

Historical Perspective

Wilson’s disease was first described by Dr. Samuel Alexander Kinnier Wilson at which he described the pathological changes in the brain and liver in 1912. Many research studies revealed the correlation between ATP7B gene mutation and Wilson’s disease. The first effective oral chelator was discovered by Dr. Walshe in 1956.

Classification

Wilson’s disease is classified based on the symptomatic presentation into hepatic and neurologic Wilson’s disease.

Pathophysiology

Copper is one of the essential elements for the human body. Copper must be absorbed and transported in order to function properly. Copper is transported bound to metallothionein or carried by ATOX1 to the trans-Golgi network. Impairment of copper incorportation in formation of ceruloplasmin will lead to increase the serum level of the copper. The increase of copper level will lead to accumulation of the excess amount in the liver and other organs. ATP7B gene mutation is found in the majority of the patients with Wilson’s disease. 

Causes

Wilson’s disease is caused by ATP7B gene mutation and impairement of copper transportation. 

Differentiating Wilson’s disease from Other Diseases

Wilson’s disease must be differentiated from other diseases that cause jaundice like hemochromatosisviral hepatitisalcoholic hepatitisdrug induced hepatitis, and autoimmune hepatitis.

Epidemiology and Demographics

The prevalence of Wilson’s disease is estimated to be 3 cases per 100,000 individuals worldwide. Wilson’s disease affects individuals between 5 to 35 years old.

Risk Factors

Commpn risk factors of Wilson’s disease include newborns of disease-carrier parents. Less common risk factors inlcude excess non-vegetarian diet.

Screening

There is insufficient evidence to recommend routine screening for Wilson’s disease.

Natural History, Complications, and Prognosis

If left untreated, Wilson’s disease will lead to death as the copper accumulation in the liver and brain results in cirrhosis and severe dystonia respectively. Common complications of Wilson’s disease include hepatocellular carcinomarenal failure, and persistent neurological manifestations. Prognosis of Wilson’s disease is usually good in case of early detection and proper treatment.

Diagnosis

Diagnostic study of choice

Wilson’s disease diagnostic criteria is based on scoring system which includes clinical presentation, laboratory findings, and gene mutation analysis. The score of 4 or more is diagnostic for Wilson’s disease. The score of 2 or less is ruling out Wilson’s disease.

History and Symptoms

Patients with Wilson’s disease may remain asymptomatic until the copper deposits in the liver and brain mainly. Common hepatic symptoms include abdominal distension, abdominal pain, fatigue, bleeding tendency, and esophageal varices. Common neuropsychiatric symptoms include tremors, ataxia, dysarthria, and impulsiveness. Less common symptoms of wilson’s disease include urolithiasis and hematuria

Physical Examination

Patients with Wilson’s disease usually appear tired. Physical examination of patients with Wilson’s disease is usually remarkable for jaundice and easy bruising in the skin. Physical examination also is remarkable for Kayser-Fleischer ring in the eyes as a result of the copper accumulation in the cornea. Common physical examination findings in the abdomen include abdominal tenderness, ascites, and spider angiomata. Common neuropsychiatric signs include seizures, parkinsonism like signs, depression, and anxiety.

Laboratory Findings

Laboratory findings suggestive for Wilson’s disease include low ceruloplasmin level, high serum copper concentration, and high urinary excretion of thecopper.

Electrocardiogram

There are no EKG findings associated with Wilson’s disease. However, if the heart is affected by Wilson’s disease, EKG should be performed to exclude any concurrentarrhythmias.

X-ray

There are no x-ray findings associated with Wilson’s disease.

Ultrasound

There are no ultrasound findings associated with Wilson’s disease.

CT scan

CT scan can be used in detecting abnormalities in the brain but MRI is more sensetive in diagnosing Wilson’s disease associated with neurological manifestations.

MRI

There are no specific MRI findings associated with Wilson’s disease especially in cases who present with only hepatic manifestations. However, it may show abnormalities in the basal ganglia in the patients who presented with neuropsychiatric manifestations.

Other Imaging Findings

There are no other imaging findings associated with Wilson’s disease.

Other Diagnostic Studies

Liver biopsy is performed in suspected cases of Wilson’s disease as it may show many histopathological features. Liver biopsy may show mild steatosis, hepatocellular necrosis, macronodular cirrhosis, and fulminant liver failure features as parenchymal collapse. Genetic testing is also recommended in Wilson’s disease to obtain the family history of the disease and for early detection.

Treatment

Medical Therapy

Medical therapy is the mainstay of therapy for treatment patients with Wilson’s disease. The treatment option include copper chelators as penicillamine and trientine. The treatment also includes Zinc to prevent copper reaccumulation.

Surgery

Surgery is not the first-line treatment option for patients with Wilson’s disease. Surgery is usually reserved for patients with acute hepatitis and unresponsive to the medical therapy. Liver transplantation is recommended in patients with acute liver failure.

Primary prevention

Effective measures for the primary prevention of Wilson’s disease include genetic analysis of the family members in order to early detect and treat the disease.

Secondary prevention

The primary and secondary prevention strategies for Wilson’s disease are the same.

References

Template:WH Template:WS

Historical Perspective

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Elsaiey, MBBCH [2]

Overview

Wilson’s disease was first described by Dr. Samuel Alexander Kinnier Wilson where he described the pathological changes in the brain and liver in 1912. Many research studies revealed the correlation between ATP7B gene mutation and Wilson’s disease. The first effective oral chelator was discovered by Dr. Walshe in 1956.

Historical perspective

Discovery

  • In 1912, the neurologist Dr. Samuel Alexander Kinnier Wilson was the first to describe Wilson’s disease. Dr. Wilson described the pathological changes in the brain and liver.[1]
  • In 1902, Dr. Kayser described the corneal rings which was abnormal pigmentation of the eye which was named after that Kayser-Fleisher rings. Dr. Wilson did not correlate between the disease and the pigmented corneal rings at the time he discovered the disease.[2]
  • In 1948, Dr. John N. Cumings described the correlation between the copper accumulation and the pathological changes that occur in the liver and the brain.[3]
  • From 1980s to 1990s, many research studies proved the linkage between the mutation of ATP7B gene and Wilson’s disease.[4][5]

Landmark Events in the Development of Treatment Strategies

  • In 1951, Dr. Cumings and Dr. Denny-Brown reported the first effective treatment against Wilson’s disease by the copper chelators.[6]
  • In 1956, Dr. Walshe discovered penicillamine which was the first effective oral chelator back then.[7]
  • In 1961, Dr. Schouwink and Dr. Hoogenraad used Zinc acetate as a medical therapy in treatment of Wilson’s disease.
  • In 1982, Dr. Walshe also described trientine as an effective chelator also for the copper.[8]

References

  1. Kinnier Wilson SA (1912). “Progressive lenticular degeneration: a familial nervous disease associated with cirrhosis of the liver” (PDF). Brain. 34 (1): 295–507. doi:10.1093/brain/34.4.295.
  2. Lorincz MT (2010). “Neurologic Wilson’s disease”. Ann N Y Acad Sci. 1184: 173–87. doi:10.1111/j.1749-6632.2009.05109.x. PMID 20146697.
  3. Cumings JN (1948). “The copper and iron content of brain and liver in the normal and in hepato-lenticular degeneration” (PDF). Brain. 71 (Dec): 410–5. doi:10.1093/brain/71.4.410. PMID 18124738.
  4. Tanzi RE, Petrukhin K, Chernov I; et al. (1993). “The Wilson disease gene is a copper transporting ATPase with homology to the Menkes disease gene”. Nat. Genet. 5 (4): 344–50. doi:10.1038/ng1293-344. PMID 8298641.
  5. Bull PC, Thomas GR, Rommens JM, Forbes JR, Cox DW (1993). “The Wilson disease gene is a putative copper transporting P-type ATPase similar to the Menkes gene”. Nat. Genet. 5 (4): 327–37. doi:10.1038/ng1293-327. PMID 8298639.
  6. Cumings JN (1951). “The effects of B.A.L. in hepatolenticular degeneration”. Brain. 74 (1): 10–22. doi:10.1093/brain/74.1.10. PMID 14830662. Unknown parameter |month= ignored (help)
  7. Walshe JM (1956). “Wilson’s disease; new oral therapy”. Lancet. 267 (6906): 25–6. doi:10.1016/S0140-6736(56)91859-1. PMID 13279157. Unknown parameter |month= ignored (help)
  8. Walshe JM (1982). “Treatment of Wilson’s disease with trientine (triethylene tetramine) dihydrochloride”. Lancet. 1 (8273): 643–7. doi:10.1016/S0140-6736(82)92201-2. PMID 6121964. Unknown parameter |month= ignored (help)

Template:WH Template:WS

Classification

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Elsaiey, MBBCH [2]

Overview

Wilson’s disease is classified based on the symptomatic presentation into hepatic and neurologic Wilson’s disease.

Classification

Wilson’s disease is classified based on the symptomatic presentation as the following:[1]

  • Hepatic Wilson’s disease (H):
  • Neurologic Wilson’s disease (N):
    • N1: Neurologic manifestations associated with hepatic involvement
    • N2: Neurologic manifestations only
    • NX: Unknown liver involvement

References

  1. Ferenci P, Caca K, Loudianos G, Mieli-Vergani G, Tanner S, Sternlieb I; et al. (2003). “Diagnosis and phenotypic classification of Wilson disease”. Liver Int. 23 (3): 139–42. PMID 12955875.

Template:WH Template:WS

Pathophysiology

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Elsaiey, MBBCH [2]

Overview

Copper is one of the essential elements for the human body. Copper must be absorbed and transported in order to function properly. Copper is transported bound to metallothionein or carried by ATOX1 to the trans-Golgi network. Impairment of copper incorportation in formation of ceruloplasmin will lead to increase the serum level of the copper. The increase of copper level will lead to accumulation of the excess amount in the liver and other organs. ATP7B gene mutation is found in the majority of the patients with Wilson’s disease.

Pathophysiology

Normal copper transportation and metabolism

Normal absorption and distribution of copper. Cu = copper, CP = ceruloplasmin, green = ATP7B carrying copper. Source:By en:User:Jfdwolff – Copper Metabolism, English Wikipedia, Public Domain, https://commons.wikimedia.org/w/index.php?curid=7777267

Pathogenesis

  • The following table includes the main mechanisms that play an important role in pathogenesis of Wilson’s disease.
Impaired copper metabolism Role in Wilson’s disease pathogenesis
Impaired copper incorporation
  • Failure of the copper to be incorporated into apoceruloplasmin leads to accumulation of the copper in the hepatocytes and different body tissues and organs.
  • Ceruloplasmin level may be decreased as a result of impaired copper incorporation. However, it is not required to diagnose Wilson’s disease.
Copper accumulation in hepatocytes
Extrahepatic copper accumulation
  • Copper accumulation will eventually lead to copper deposition in other organs like the brain.
  • The urinary excretion of the copper will not be able to decrease the serum levels and the deposition increases over time ending by the damage of the other organs especially the brain.

Genetics

Associated conditions

Gross pathology

Images courtesy of Professor Peter Anderson DVM PhD and published with permission © PEIR, University of Alabama at Birmingham, Department of Pathology

Microscopic pathology

  • Histological examination of a liver biopsy may show the following:[6]
    • Mild steatosis which is considered an early histological feature
    • Glycogenated hepatic nuclei
    • Hepatocellular necrosis
    • Autoimmune hepatitis histologic features
    • Fibrosis and cirrhosis (macronodular or micronodular) in advanced cases
    • Fulminant liver falilure features which include:
      • Hepatocellular degenration
      • Parenchymal collapse

References

  1. Sandstead HH (1982). “Copper bioavailability and requirements”. Am J Clin Nutr. 35 (4): 809–14. PMID 6280488.
  2. Sandstead HH (1982). “Copper bioavailability and requirements”. Am J Clin Nutr. 35 (4): 809–14. PMID 6280488.
  3. Pfeiffer RF (2007). “Wilson’s Disease”. Semin Neurol. 27 (2): 123–32. doi:10.1055/s-2007-971173. PMID 17390257.
  4. Hung IH, Suzuki M, Yamaguchi Y, Yuan DS, Klausner RD, Gitlin JD (1997). “Biochemical characterization of the Wilson disease protein and functional expression in the yeast Saccharomyces cerevisiae”. J Biol Chem. 272 (34): 21461–6. PMID 9261163.
  5. de Bie, P; Muller, P; Wijmenga, C; Klomp, L W J (2007). “Molecular pathogenesis of Wilson and Menkes disease: correlation of mutations with molecular defects and disease phenotypes”. Journal of Medical Genetics. 44 (11): 673–688. doi:10.1136/jmg.2007.052746. ISSN 1468-6244.
  6. Kim TJ, Kim IO, Kim WS, Cheon JE, Moon SG, Kwon JW; et al. (2006). “MR imaging of the brain in Wilson disease of childhood: findings before and after treatment with clinical correlation”. AJNR Am J Neuroradiol. 27 (6): 1373–8. PMID 16775300.

Template:WH Template:WS

Causes

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Elsaiey, MBBCH [2]

Overview

Wilson’s disease is caused by ATP7B gene mutation and impairement of copper transportation.

Causes

References

  1. Bull PC, Thomas GR, Rommens JM, Forbes JR, Cox DW (1993). “The Wilson disease gene is a putative copper transporting P-type ATPase similar to the Menkes gene”. Nat Genet. 5 (4): 327–37. doi:10.1038/ng1293-327. PMID 8298639.
  2. Tanzi RE, Petrukhin K, Chernov I, Pellequer JL, Wasco W, Ross B; et al. (1993). “The Wilson disease gene is a copper transporting ATPase with homology to the Menkes disease gene”. Nat Genet. 5 (4): 344–50. doi:10.1038/ng1293-344. PMID 8298641.

Template:WH Template:WS

Differentiating Wilson’s disease from other Diseases

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Elsaiey, MBBCH [2]

Overview

Wilson’s disease must be differentiated from other diseases that cause jaundice like hemochromatosis, viral hepatitis, alcoholic hepatitis, drug induced hepatitis, and autoimmune hepatitis.

Differentiating Wilson’s disease from other diseases

The differential diagnosis for jaundice, click here.

The differential diagnosis for jaundice and RUQ pain, click here.

The differential diagnosis for jaundice and pruritis, click here.

The differential diagnosis for jaundice and fever, click here.

The differential diagnosis for jaundice, fever, and RUQ pain, click here.

The differential diagnosis for jaundice, pruritis and RUQ pain, click here.


Differential diagnosis of jaundice are: [1][2][3][4][5]

Classification of jaundice based on etiology Disease History and clinical manifestations Diagnosis
Lab Findings Other blood tests Other diagnostic
Family history Fever RUQ Pain Pruritis AST ALT ALP BLR Indirect BLR Direct Viral serology
Jaundice Hepatocellular Jaundice Infiltrative liver disorders: Hemochromatosis, amyloidosis + -/+ ↑/N ↑/N N Ferritin ↑ (hemochromatosis) Liver biopsy
Wilson’s disease + -/+ N ↑/N N ↑ Serum ceruloplasmin Liver biopsy
Viral hepatitis -/+ N ↑/N N + Specific viral antibody for each type
Alcoholic hepatitis -/+ -/+ ↑↑ N ↑/N N
Drug induced hepatitis -/+ N ↑/N N
Autoimmune hepatitis -/+ -/+ N ↑/N N Anti-LKM antibody Liver biopsy
Cirrhosis -/+ -/+ -/+ ↑/N ↑/N ↑/N -/+ Low platate Small liver on ultrasond
Nonalcoholic steatohepatitis -/+ N ↑/N N Dyslipidemia liver biopsy
Ischemic hepatopathy -/+ -/+ N ↑/N N Cardiovascular risk factors
Cholestatic Jaundice Common bile duct stone -/+ + + N N N Dilated ducts on ultrasound CT/ERCP
Hepatitis A (cholestatic type) -/+ + + N/↑ N/↑ N + HAV- Ab Abdominal ultrasound
EBV / CMV hepatitis -/+ + + N N N + Positive serology
Primary biliary cirrhosis -/+ -/+ + N/↑ N/↑ N AMA positive Liver biopsy
Primary sclerosing cholangitis -/+ -/+ + N/↑ N/↑ N ↑Autoantibodies (P-ANCA), hypergammaglobulinemia MRCP,

Liver biopsy

Sickle cell disease + +/- N/↑ N/↑ N Genetic testing
Pancreatic carcinoma + -/+ -/+ N/↑ N/↑ N CT scan for diagnosis
AIDS cholangiopathy -/+ -/+ N/↑ N/↑ N HIV Ab Ultrasound or ERCP
Parasites induces cholestasis -/+ -/+ N/↑ N/↑ N Serology Ultrasound or ERCP
Intrahepatic cholestasis of pregnancy -/+ -/+ + N Thrombocytopenia Diagnosed clinically
Isolated Jaundice Crigler-Najjar type 2 + N N N Genetic testing
Gilbert + N N N Genetic testing
Rotor syndrome + N N N N Genetic testing Liver biopsy
Dubin-Johnson syndrome + N N N N Genetic testing Liver biopsy
Hereditary spherocytosis + -/+ N N N N Genetic testing Osmotic fragility
G6PD deficiency + N N N N Genetic testing
Thalassemia + N N N N Genetic testing
Paroxysmal nocturnal hemoglobinuria N N N N Flocytometery
Immune hemolysis -/+ N N N N Autoantibodies
Hematoma -/+ N N N N Anemia Truma or surgery in history

References

  1. Fargo MV, Grogan SP, Saguil A (2017). “Evaluation of Jaundice in Adults”. Am Fam Physician. 95 (3): 164–168. PMID 28145671.
  2. Leevy CB, Koneru B, Klein KM (1997). “Recurrent familial prolonged intrahepatic cholestasis of pregnancy associated with chronic liver disease”. Gastroenterology. 113 (3): 966–72. PMID 9287990.
  3. Hov JR, Boberg KM, Karlsen TH (2008). “Autoantibodies in primary sclerosing cholangitis”. World J. Gastroenterol. 14 (24): 3781–91. PMC 2721433. PMID 18609700.
  4. Bond LR, Hatty SR, Horn ME, Dick M, Meire HB, Bellingham AJ (1987). “Gall stones in sickle cell disease in the United Kingdom”. Br Med J (Clin Res Ed). 295 (6592): 234–6. PMC 1247079. PMID 3115390.
  5. Malakouti M, Kataria A, Ali SK, Schenker S (2017). “Elevated Liver Enzymes in Asymptomatic Patients – What Should I Do?”. J Clin Transl Hepatol. 5 (4): 394–403. doi:10.14218/JCTH.2017.00027. PMC 5719197. PMID 29226106.
Epidemiology and Demographics

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Elsaiey, MBBCH [2]

Overview

The prevalence of Wilson’s disease is estimated to be 3 cases per 100,000 individuals worldwide. Wilson’s disease affects individuals between 5 to 35 years old.

Epidemiology and demographics

Prevalence

  • The prevalence of Wilson’s disease is estimated to be 3 cases per 100,000 individuals worldwide.[1]

Age

  • Wilson’s disease commonly affects inidividuals between 5 to 35 years old.

Race

  • There is no racial predilection to Wilson’s disease.

Gender

  • Wilson’s disease affects men and women equally.

References

  1. Huster D (2010). “Wilson disease”. Best Pract Res Clin Gastroenterol. 24 (5): 531–9. doi:10.1016/j.bpg.2010.07.014. PMID 20955957.
Risk Factors

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Elsaiey, MBBCH [2]

Overview

Commpn risk factors of Wilson’s disease include newborns of disease-carrier parents. Less common risk factors inlcude excess non-vegetarian diet.

Risk factors

Common risk factors of Wilson’s disease include the following:[1]

  • Newborns of parents who are carriers of the disease

Less common risk factors of Wilson’s disease include:

  • Excess non-vegetarian diet

References

  1. Bull PC, Thomas GR, Rommens JM, Forbes JR, Cox DW (1993). “The Wilson disease gene is a putative copper transporting P-type ATPase similar to the Menkes gene”. Nat Genet. 5 (4): 327–37. doi:10.1038/ng1293-327. PMID 8298639.
Screening

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Elsaiey, MBBCH [2]

Overview

There is insufficient evidence to recommend routine screening for Wilson’s disease.

Screening

There is insufficient evidence to recommend routine screening for Wilson’s disease.

References

Template:WH Template:WS

Natural History, Complications and Prognosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Elsaiey, MBBCH [2]

Overview

If left untreated, Wilson’s disease will lead to death as the copper accumulation in the liver and brain will lead to cirrhosis and severe dystonia respectively. Common complications of Wilson’s disease include hepatocellular carcinoma, renal failure, and persistent neurological manifestations. Prognosis of Wilson’s disease is usually good in case of early detection and proper treatment.

Natural History, Complications, and Prognosis

Natural history

  • The symptoms of Wilson’s disease usually develop between age of 5 and 35 years. However, the symptoms can be presented at any age onset.
  • If left untreated, Wilson’s disease will lead to death. The copper accumulation in the liver and the brain will end up with cirrhosis and severe dystonia respectively. [1]

Complications

Prognosis

  • Prognosis of Wilson’s disease is usually good with early detection and proper treatment except in the severely advanced patients.

References

  1. European Association for Study of Liver (2012). “EASL Clinical Practice Guidelines: Wilson’s disease”. J Hepatol. 56 (3): 671–85. doi:10.1016/j.jhep.2011.11.007. PMID 22340672.
Diagnosis

Diagnosis

Wilson’s disease diagnostic study of choice | History and Symptoms | Physical Examination | Laboratory Findings | Electrocardiogram | X-ray | CT | Echocardiography or Ultrasound | Other Imaging Findings | Other Diagnostic Studies

Treatment

Treatment

Medical Therapy | Surgery | primary prevention | secondary prevention | Cost-effectiveness of Therapy | Future or Investigational Therapies Template:Mineral metabolic pathology


Template:Link FA

ar:مرض ويلسون ca:Malaltia de Wilson de:Morbus Wilson it:Malattia di Wilson he:מחלת וילסון lb:Wilson-Krankheet hu:Wilson-kór nl:Ziekte van Wilson fi:Wilsonin tauti

Template:WH Template:WS

Looking for the patient version?

Back to the patient-friendly article

© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH